Akil Handan, Burgess Jamie, Nevitt Sarah, Harding Simon P, Alam Uazman, Burgess Philip
Department of Eye and Vision Science, Institute of Life Course and Medical Sciences, University of Liverpool and St. Paul's Eye Unit, Liverpool University Hospitals NHS Trust, Liverpool, UK.
Diabetes and Endocrinology Research, Institute of Cardiovascular and Metabolic Medicine and The Pain Research Institute, University of Liverpool and Liverpool University NHS Hospital Trust, Liverpool, UK.
Diabetes Ther. 2022 Jan;13(1):1-23. doi: 10.1007/s13300-021-01190-z. Epub 2021 Dec 20.
To systematically review the epidemiology of early worsening of diabetic retinopathy (EWDR) after substantial improvements in glycaemic control and evaluate characteristics including risk factors. This systematic review was registered with PROSPERO (CRD42020158252). An electronic literature search was performed according to PRISMA guidelines using MEDLINE, EMBASE, PubMed, Web of Science, Scopus and Cochrane databases and manual reference for the articles published until 2020. Published full-text English language articles that report data on diabetic retinopathy in people with diabetes experiencing a rapid, substantial decrease in HbA1c after going through intensive therapy were included. All articles were screened, data were extracted and methodological quality was evaluated by two independent reviewers using a priori criteria. A total of 346 articles were identified after the removal of duplicates. Data were extracted from 19 full-text articles with a total of 15,588 participants. Included studies varied considerably in terms of patient selection, timing and method of assessing the eye and retinopathy classification. EWDR was reported to occur in a wide range of prevalences; 3.3-47% of participants within 3-84 months after intensification of glycaemic control. Risk factors for EWDR included long duration of diabetes, long-term uncontrolled hyperglycemia, amplitude of and baseline retinopathy severity in both type 1 and type 2 diabetes. The occurrence of EWDR and progression of retinopathy were found to have an association with the amplitude of HbA1c reduction. EWDR has been described in a proportion of people with intensification of glycaemic control. However, the prevalence remains unclear because of methodological differences in the identified studies. Future interventional studies should report retinopathy and visual outcomes using standardized protocols.
系统评价血糖控制显著改善后糖尿病视网膜病变早期恶化(EWDR)的流行病学,并评估包括危险因素在内的特征。本系统评价已在国际前瞻性系统评价注册库(PROSPERO,注册号:CRD42020158252)登记。根据PRISMA指南,使用MEDLINE、EMBASE、PubMed、Web of Science、Scopus和Cochrane数据库进行电子文献检索,并手动查阅截至2020年发表的文章。纳入发表的英文全文文章,这些文章报告了糖尿病患者在强化治疗后糖化血红蛋白(HbA1c)迅速大幅下降时糖尿病视网膜病变的数据。由两名独立评审员使用预先设定的标准对所有文章进行筛选、提取数据并评估方法学质量。去除重复项后共识别出346篇文章。从19篇全文文章中提取数据,共有15588名参与者。纳入的研究在患者选择、评估眼睛的时间和方法以及视网膜病变分类方面差异很大。据报道,EWDR的发生率范围很广;在血糖控制强化后3 - 84个月内,3.3% - 47%的参与者出现EWDR。EWDR的危险因素包括糖尿病病程长、长期血糖控制不佳、1型和2型糖尿病患者糖化血红蛋白下降幅度以及基线视网膜病变严重程度。发现EWDR的发生和视网膜病变的进展与HbA1c降低幅度有关。在一部分血糖控制强化的人群中描述了EWDR。然而,由于已识别研究中的方法学差异,其患病率仍不清楚。未来的干预性研究应使用标准化方案报告视网膜病变和视力结果。